GCA Advises Takara Bio USA Holdings, Inc. on Its Acquisition of Rubicon Genomics, Inc.
We are pleased to announce that on January 17, 2017, our client, Takara Bio USA Holdings, Inc., completed the acquisition of Rubicon Genomics, Inc.
Takara Bio USA Holdings, Inc. is a US-based, wholly owned subsidiary of Takara Bio Inc., a leading global biotechnology and life science company headquartered in Shiga, Japan. Rubicon Genomics, Inc., headquartered in Ann Arbor, Michigan, is a leading provider of pre-analytical library preparation kits that increase the accuracy, efficiency and speed of genomic analysis.
The acquisition will allow the Takara Bio Group (which includes Takara Bio Inc., Takara Bio USA, Inc. and other Takara Bio affiliates) to augment and expand its worldwide commercial offerings in next generation sequencing sample preparation and expand into new markets.
The transaction is subject to customary closing conditions.
GCA acted as exclusive financial advisor to Takara Bio USA Holdings, Inc. in connection with this transaction.
A link to Takara Bio’s press release is here.
About Takara Bio, Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio Inc. was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio Inc. has active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, Takara Bio Inc. aims to extend its reach around the world. For more information, visit takara-bio.com.
About Takara Bio USA, Inc.
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures and distributes a wide range of life science research reagents under the Takara®, Clontech® and Cellartis® brands. Key products include SMARTer® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium® and Advantage® enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART® library construction kits; the innovative In-Fusion® cloning system; Guide-it™ gene editing tools; Tet-based inducible gene expression systems; and Living Colors® fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation and function studies; protein expression and purification; gene editing and stem cell studies; and plant and food research. For more information, visit www.takarabio.com.
About Rubicon Genomics, Inc.
Rubicon Genomics, Inc. develops innovative, high quality, nucleic acid library preparation and companion products for research applications that enable easy, reliable and highly sensitive analysis of samples. Rubicon Genomics, Inc. is committed to teamwork and continuous improvement to provide excellence to customers, shareholders and employees. Privately-held Rubicon Genomics, Inc. is located in Ann Arbor, Michigan. For more information, visit www.rubicongenomics.com.
GCA is a premier global investment bank serving a broad client base through a range of advisory services including mergers and acquisitions, debt and equity capital markets, private funds, restructuring, and asset management. GCA is a global advisor providing unbiased, insightful advice and is focused on building long-term relationships based on trust. GCA delivers deep expertise in many key industries and has a particular focus in Technology, Software, Media, Digital Media, Communications, Industrials and Industrial Technology, Healthcare, Financial Institutions, FinTech and Business Services. GCA has teams of highly experienced bankers in San Francisco, New York, Tokyo, Frankfurt, London, Manchester, Milan, Mumbai, Munich, Osaka, Shanghai, Singapore, Tel Aviv and Zurich. For more information, visit www.gcaglobal.com.